JAK2 and sarcoidosis: Hence, we treated the macrophage granuloma aggregates of sarcoidosis patients with Tofacitinib, a JAK2/3 inhibitor that was shown to be effective in treating patients with longstanding cutaneous sarcoidosis (19, 31).